Antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by 2050 — already responsible for 1.27 million deaths worldwide in 2019. Hospital antibiotic stewardship programs (ASPs) are the primary institutional mechanism for reducing inappropriate antibiotic use, improving clinical outcomes, and slowing resistance emergence. Joint Commission and CMS now require ASPs in accredited hospitals.
Evidence That ASPs Work
A 2014 Cochrane review (221 studies) found hospital ASPs significantly reduce: inappropriate antibiotic prescribing (relative risk reduction ~35%), Clostridioides difficile infection rates (significant reduction in 80% of studies examining C. diff), antibiotic costs (mean $337,000 annual savings per hospital), and length of stay. Importantly: most studies show no increase in clinical failure rates or mortality with ASP implementation — the concern that restricting antibiotics harms patients is not supported by evidence when appropriate interventions are targeted. The key evidence base: restricting inappropriate antibiotics does not worsen outcomes; it reduces C. diff, reduces selection pressure for resistance, and reduces adverse effects (drug toxicity, drug-drug interactions) from unnecessary broad-spectrum agents.
Core ASP Interventions
Two most evidence-supported strategies: (1) Prospective audit and feedback (PAF): pharmacist/ID physician review of antibiotic prescriptions at 48–72 hours, with recommendations to prescribers regarding de-escalation, dose optimization, or discontinuation. Meta-analysis: PAF reduces total antibiotic consumption by 24% and broad-spectrum use by 32%. Preferred over prior authorization for preserving prescriber relationship and flexibility. (2) Formulary restriction and prior authorization: requiring approval for restricted agents (carbapenems, daptomycin, voriconazole) from ID team before dispensing. Highly effective at reducing targeted agent use — requires sufficient ID physician time to be sustainable. De-escalation: stepping antibiotic coverage from empiric broad-spectrum to culture-guided narrow-spectrum is the single highest-impact individual ASP intervention — supported by every major guideline but consistently underperformed in practice (40–60% of appropriate de-escalation opportunities missed). IV-to-oral conversion: switching IV antibiotics to bioequivalent oral formulations (fluoroquinolones, metronidazole, linezolid, clindamycin have >90% oral bioavailability) reduces costs, line complications, and length of stay with no clinical harm. For hospital pharmacy, infectious disease, and clinical programs implementing ASP infrastructure, our laboratory supplies section supports microbiological culture collection, and our PPE catalog ensures infection control compliance throughout antibiotic stewardship programs.
